Walleye Capital LLC bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 718,897 shares of the biotechnology company's stock, valued at approximately $1,783,000. Walleye Capital LLC owned about 1.01% of Aclaris Therapeutics as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. ExodusPoint Capital Management LP purchased a new position in shares of Aclaris Therapeutics during the 4th quarter valued at about $26,000. Invesco Ltd. bought a new position in shares of Aclaris Therapeutics in the fourth quarter worth approximately $28,000. Commonwealth Equity Services LLC purchased a new position in shares of Aclaris Therapeutics in the fourth quarter worth $36,000. Charles Schwab Investment Management Inc. purchased a new stake in Aclaris Therapeutics during the 4th quarter valued at $82,000. Finally, XTX Topco Ltd purchased a new position in shares of Aclaris Therapeutics in the fourth quarter valued at about $111,000. Hedge funds and other institutional investors own 98.34% of the company's stock.
Analysts Set New Price Targets
ACRS has been the topic of several recent analyst reports. Cantor Fitzgerald started coverage on Aclaris Therapeutics in a research note on Tuesday, March 18th. They issued an "overweight" rating on the stock. StockNews.com cut Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 8th. Finally, Scotiabank started coverage on Aclaris Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target for the company. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Aclaris Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $11.67.
Get Our Latest Stock Report on ACRS
Aclaris Therapeutics Stock Performance
Shares of Aclaris Therapeutics stock traded up $0.07 during trading on Friday, hitting $1.34. The company's stock had a trading volume of 150,770 shares, compared to its average volume of 1,189,800. The company has a fifty day simple moving average of $1.58 and a two-hundred day simple moving average of $2.23. Aclaris Therapeutics, Inc. has a 52 week low of $0.95 and a 52 week high of $5.17. The company has a market capitalization of $144.56 million, a PE ratio of -2.57 and a beta of 0.53.
Aclaris Therapeutics Profile
(
Free Report)
Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Further Reading
Before you consider Aclaris Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.
While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
